Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

DISEASE CHARACTERISTICS:

• Histologically confirmed glioblastoma multiforme
• Focal disease
• Progressive or recurrent disease after prior treatment with radiotherapy and/or chemotherapy
• Low-grade astrocytoma that progressed to glioblastoma multiforme after prior radiotherapy and/or chemotherapy allowed
• Gross tumor volume 5-60 mL
• No intraventricular tumor, infratentorial tumor, or tumor that communicates with the ventricles
• No bilateral non-contiguous gadolinium-enhancing tumor
• No diffuse disease, defined as any satellite lesion > 1.5 cm from the anticipated location of a catheter tip OR > 2 satellite lesions
• No ventricular invasion outside the anticipated radiotherapy volume

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• Karnofsky 60-100%

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 9.0 g/dL

Hepatic

• Bilirubin ≤ 1.5 mg/dL
• AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• Hepatitis B negative
• No evidence of active hepatitis

Renal

• Creatinine ≤ 1.7 mg/dL
• BUN ≤ 2 times ULN

Cardiovascular

• No uncontrolled hypertension
• No unstable angina pectoris
• No uncontrolled cardiac dysrhythmia

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to undergo MRI
• Mini Mental State Exam score ≥ 15
• No serious infection
• No other medical illness that would preclude study participation
• No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer
• No psychological or sociological condition, addictive disorder, or other condition that would preclude study compliance
• No known or suspected allergy to study drug or iodine
• No known HIV positivity

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No prior monoclonal antibodies
• No prior local immunotherapy or treatment with the following biologic agents:
• Immunotoxins
• Immunoconjugates
• Antiangiogenesis compounds
• Antisense agents
• Peptide receptor antagonist
• Interferons
• Interleukins
• Tumor infiltrating lymphocytes
• Lymphokine-activated killer cells
• Gene therapy

Chemotherapy

• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
• At least 3 months since prior polifeprosan 20 with carmustine implant (Gliadel wafer^® )

Endocrine therapy

• Must be maintained on a stable corticosteroid dose (approximately 4 mg) for ≥ 2 weeks before study entry

Radiotherapy

• See Disease Characteristics
• At least 3 months since prior radiotherapy
• No prior brachytherapy or radiosurgery

Surgery

• At least 4 weeks since prior surgery

Other

• Recovered from all prior therapy
• At least 1 month since prior investigational agents
• No more than 2 prior treatment regimens
• No other prior local therapy